stockrow
Saturday 7 November 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million.
- EPS
- −8.22%
- Free cash flow
- +10.0%
Quarter to September 2026, against a year earlier
9.42
0.61
+6.92%
Follow CTNM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
30.45 | 36.25 | 37.00 | 26.98 | |
Current Ratio |
31.11 | 37.17 | 38.00 | 27.50 | |
Net Debt/EBITDA |
11.71 | 13.68 | 14.64 | 15.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.59 | 0.76 | 1.13 | 0.86 | |
Capex/Depreciation |
0.00 | (0.04) | (3.76) | (0.49) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.31) | (0.44) | (0.47) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.29) | (0.31) | (0.44) | (0.47) | |
Cash per Share |
6.37 | 6.31 | 6.60 | 9.49 | |
Shareholders Equity per Share |
6.39 | 6.40 | 6.70 | 9.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.39 | 6.40 | 6.70 | 9.42 | |
Free Cash Flow |
(11.06) | (11.51) | (16.58) | (13.08) | |
Working Capital |
241.72 | 236.05 | 246.31 | 258.17 | |
Capital Expenditures |
0.00 | (0.01) | (0.31) | (0.04) | |
Net Current Asset Value |
238.17 | 231.87 | 241.66 | 252.26 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.71 | 1.25 | 2.57 | 1.41 | |
Average Assets |
223.92 | 216.63 | 229.81 | 244.74 | |
Average Common Equity |
212.94 | 205.53 | 217.40 | 229.53 |
Columns are period end dates · fundamentals updated 5 Nov 2026